MET proto-oncogene, receptor tyrosine kinase. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Cabozantinib CHEMBL2105717 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 48 |
| Amivantamab CHEMBL4297774 |
Hepatocyte growth factor receptor inhibitor Inhibitor Antibody |
✓ Both | 31 |
| Crizotinib CHEMBL601719 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Savolitinib CHEMBL3334567 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Cabozantinib S-malate CHEMBL2103868 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 10 |
| Capmatinib CHEMBL3188267 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 5 |
| Telisotuzumab vedotin CHEMBL3990032 |
Hepatocyte growth factor receptor binding agent Binding agent Antibody drug conjugate |
✓ Both | 4 |
| Tepotinib CHEMBL3402762 |
Hepatocyte growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Colorectal cancer | 5 | Phase 3 |
| Cancer | 4 | Phase 3 |
| Non-small cell lung carcinoma | 4 | Phase 3 |
| Glioblastoma | 4 | Phase 1/2 |
| Breast cancer | 3 | Phase 2 |
| Hepatocellular carcinoma | 3 | Phase 2 |
| Clear cell renal carcinoma | 2 | Phase 3 |
| Differentiated thyroid carcinoma | 2 | Phase 3 |
| Head and neck squamous cell carcinoma | 2 | Phase 3 |
| Non-small cell squamous lung carcinoma | 2 | Phase 3 |
| Papillary renal cell carcinoma | 2 | Phase 3 |
| Prostate cancer | 2 | Phase 3 |
| Soft tissue sarcoma | 2 | Phase 3 |
| Osteosarcoma | 2 | Phase 2/3 |
| Ewing sarcoma | 2 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
